ZEVRA THERAPEUTICS, INC.
ZVRADrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ZVRA Earnings Report
EPS Est: $0.08 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
How ZVRA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KP415 oral capsule | Phase 3 | ADHD | - | - |
Serdexmethylphenidate | Phase 2 | Idiopathic Hypersomnia | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ZEVRA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in ZEVRA THERAPEUTICS, INC.'s (ZVRA) pipeline across Phase 3, Phase 2. Its lead program is KP415 oral capsule (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ZEVRA THERAPEUTICS, INC.'s next FDA catalyst?→
ZEVRA THERAPEUTICS, INC.'s (ZVRA) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZVRA biotech catalysts?→
Add ZVRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ZEVRA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.